Korean Market
EXCH
Yuyu Pharma
★

Yuyu Pharma Files First Corporate Governance Report: Weak Shareholder Communication & Dividend Predictability, but Efforts Include e-Voting & Share Buyback

 
PERI
Yuyu Pharma
★★

Yuyu Pharma Q1 2026 Consolidated Sales 35.5B Won, OP 4.3B Won; Strong Parent Growth YoY

 
OWNR
Yuyu Pharma
★

Large Shareholding Report Filed (Including Acquisition Price Correction)

 
EXCH
Yuyu Pharma
★

Yuyu Pharmaceutical Largest Shareholder Stake Slightly Increases